Literature DB >> 34029690

Nicotinamide N-methyl transferase (NNMT): An emerging therapeutic target.

Yongzhi Gao1, Nathaniel I Martin2, Matthijs J van Haren3.   

Abstract

Nicotinamide N-methyltransferase (NNMT) methylates nicotinamide (NA) to generate 1-methyl nicotinamide. Since its discovery 70 years ago, the appreciation of the role of NNMT in human health has evolved from serving only metabolic functions to also being a driving force in diseases, including a variety of cancers. Despite the increasing evidence indicating NNMT as a viable therapeutic target, the development of cell-active inhibitors against this enzyme is lacking. In this review, we provide an overview of the current status of NNMT inhibitor development, relevant in vitro and in vivo studies, and a discussion of the challenges faced in the development of NNMT inhibitors.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cancer; Inhibitors; Metabolic disorder; NNMT; Neurodegenerative disease; Nicotinamide; S-adenosyl-l-methionine

Mesh:

Substances:

Year:  2021        PMID: 34029690     DOI: 10.1016/j.drudis.2021.05.011

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  7 in total

1.  Ligand-based in silico identification and biological evaluation of potential inhibitors of nicotinamide N-methyltransferase.

Authors:  Unnati Kushavah; Lalita Panigrahi; Shakil Ahmed; Mohammad Imran Siddiqi
Journal:  Mol Divers       Date:  2022-07-06       Impact factor: 2.943

2.  Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.

Authors:  Anna Reustle; Lena-Sophie Menig; Patrick Leuthold; Ute Hofmann; Viktoria Stühler; Christian Schmees; Michael Becker; Mathias Haag; Verena Klumpp; Stefan Winter; Florian A Büttner; Steffen Rausch; Jörg Hennenlotter; Falko Fend; Marcus Scharpf; Arnulf Stenzl; Jens Bedke; Matthias Schwab; Elke Schaeffeler
Journal:  Clin Transl Med       Date:  2022-06

Review 3.  Nicotinamide N-Methyltransferase: An Emerging Protagonist in Cancer Macro(r)evolution.

Authors:  Richard B Parsons; Paul D Facey
Journal:  Biomolecules       Date:  2021-09-28

Review 4.  Nicotinamide N-Methyltransferase in Head and Neck Tumors: A Comprehensive Review.

Authors:  Lucrezia Togni; Marco Mascitti; Davide Sartini; Roberto Campagna; Valentina Pozzi; Eleonora Salvolini; Annamaria Offidani; Andrea Santarelli; Monica Emanuelli
Journal:  Biomolecules       Date:  2021-10-28

5.  Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells.

Authors:  Xi Liu; Yuanfeng Huang; Jun Wang; Pan Li; Minqiang Yang; Shanshan Zeng; Danyang Chen; Qian Wang; Hao Liu; Kai Luo; Jin Deng
Journal:  Cell Death Discov       Date:  2022-04-06

Review 6.  Nicotinamide N-Methyltransferase as Promising Tool for Management of Gastrointestinal Neoplasms.

Authors:  Valentina Pozzi; Roberto Campagna; Davide Sartini; Monica Emanuelli
Journal:  Biomolecules       Date:  2022-08-24

7.  Alterations in Kynurenine and NAD+ Salvage Pathways during the Successful Treatment of Inflammatory Bowel Disease Suggest HCAR3 and NNMT as Potential Drug Targets.

Authors:  Artur Wnorowski; Sylwia Wnorowska; Jacek Kurzepa; Jolanta Parada-Turska
Journal:  Int J Mol Sci       Date:  2021-12-16       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.